

August 10, 2021

Result posting of ARGX-113-1804 (2019-000361-21)

Protocol title Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia


Protocol number ARGX-113-1804

Dear Madam/Sir

The ARGX-113-1804 has been prematurely ended. The sponsor has decided to change the clinical development strategy for the above mentioned indication. All ongoing activities have been terminated as of April 30th 2019. No subjects were recruited and no sites were activated, as such no (partial) results are available.

Yours sincerely

DocuSigned by:
Adeline Boucher

 Signer Name: Adeline Boucher
Signing Reason: I approve this document
Signing Time: 10-Aug-2021 | 2:41 PM CEST
A5EF217A7BE6458BA44164A812000A64

Adeline Boucher
Head of Regulatory Affairs – Europe

Together
We Discover

Belgium
Industriepark-Zwijnaarde 7
9052 Zwijnaarde (Gent)

USA
33 Arch Street, 32nd floor
Boston, MA 02110

Japan
2-5-8, Akasaka, Minato-ku
Tokyo 106-0047

T: +32 9 310 34 00
ON: BE 0.818.292.196
IBAN: BE46 7370 2845 9136
info@argenx.com www.argenx.com